Edwards Lifesciences Corp (EW) CFO Sells $3,429,250.00 in Stock

Edwards Lifesciences Corp (NYSE:EW) CFO Scott B. Ullem sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 4th. The shares were sold at an average price of $137.17, for a total transaction of $3,429,250.00. Following the completion of the sale, the chief financial officer now owns 35,968 shares of the company’s stock, valued at $4,933,730.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

EW opened at $137.51 on Friday. The company has a quick ratio of 1.41, a current ratio of 1.80 and a debt-to-equity ratio of 0.15. Edwards Lifesciences Corp has a 52-week low of $92.90 and a 52-week high of $143.22. The company has a market cap of $29,594.44, a price-to-earnings ratio of 36.19, a price-to-earnings-growth ratio of 2.07 and a beta of 0.58.

How to Become a New Pot Stock Millionaire

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, February 1st. The medical research company reported $0.94 EPS for the quarter, topping analysts’ consensus estimates of $0.91 by $0.03. Edwards Lifesciences had a net margin of 18.11% and a return on equity of 27.78%. The business had revenue of $888.50 million for the quarter, compared to analysts’ expectations of $868.45 million. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 15.7% compared to the same quarter last year. research analysts predict that Edwards Lifesciences Corp will post 4.52 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Bank of New York Mellon Corp lifted its position in shares of Edwards Lifesciences by 45.7% during the fourth quarter. Bank of New York Mellon Corp now owns 7,580,924 shares of the medical research company’s stock worth $854,444,000 after purchasing an additional 2,377,444 shares in the last quarter. Atlantic Trust Group LLC lifted its position in shares of Edwards Lifesciences by 734.7% during the third quarter. Atlantic Trust Group LLC now owns 914,989 shares of the medical research company’s stock worth $100,018,000 after purchasing an additional 805,370 shares in the last quarter. Two Sigma Advisers LP lifted its position in shares of Edwards Lifesciences by 827.6% during the fourth quarter. Two Sigma Advisers LP now owns 855,189 shares of the medical research company’s stock worth $96,388,000 after purchasing an additional 763,000 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Edwards Lifesciences by 12.1% during the fourth quarter. Alliancebernstein L.P. now owns 6,259,771 shares of the medical research company’s stock worth $705,539,000 after purchasing an additional 675,216 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in shares of Edwards Lifesciences by 488.1% during the fourth quarter. Two Sigma Investments LP now owns 708,644 shares of the medical research company’s stock worth $79,871,000 after purchasing an additional 588,148 shares in the last quarter. 82.90% of the stock is currently owned by institutional investors and hedge funds.

A number of research firms recently issued reports on EW. Zacks Investment Research downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday. Cowen restated a “buy” rating and issued a $165.00 target price on shares of Edwards Lifesciences in a report on Tuesday, March 20th. Guggenheim reiterated a “buy” rating and set a $162.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. JMP Securities boosted their price objective on shares of Edwards Lifesciences from $135.00 to $140.00 and gave the stock a “market outperform” rating in a research note on Friday, February 2nd. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences in a research note on Friday, February 2nd. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $144.16.

WARNING: “Edwards Lifesciences Corp (EW) CFO Sells $3,429,250.00 in Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/edwards-lifesciences-corp-ew-cfo-sells-3429250-00-in-stock-2.html.

About Edwards Lifesciences

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply